
Fluidigm Corporation EBITDA 2011-2026 | FLDM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -35.1 M | -36 M | -31.6 M | -39.8 M | -55.3 M | -38 M | -27.3 M | -14.8 M | -15.9 M | -14.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.5 M | -55.3 M | -30.8 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
-5 M | - | - | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-749 M | $ 29.8 | -3.87 % | $ 321 M | ||
|
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M | ||
|
BioNano Genomics
BNGO
|
-90 M | $ 1.13 | -3.54 % | $ 1.44 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | ||
|
Co-Diagnostics
CODX
|
-41.5 M | - | - | $ 79.8 M | ||
|
Celcuity
CELC
|
-113 M | $ 104.25 | 0.08 % | $ 4.11 B | ||
|
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
24.7 M | - | - | $ 914 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.84 B | $ 209.75 | 2.09 % | $ 23.3 B | ||
|
Danaher Corporation
DHR
|
5.58 B | $ 219.93 | 0.09 % | $ 161 B | ||
|
DexCom
DXCM
|
784 M | - | - | $ 26.3 B | ||
|
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | ||
|
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-189 M | $ 19.51 | -5.18 % | $ 1.05 B | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
-55.7 M | $ 11.07 | 1.37 % | $ 314 M | ||
|
Exact Sciences Corporation
EXAS
|
-757 M | $ 103.42 | - | $ 19.2 B | ||
|
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
8.41 M | $ 1.82 | - | $ 7.98 M | ||
|
Fulgent Genetics
FLGT
|
-49 M | $ 23.02 | - | $ 696 M | ||
|
Guardant Health
GH
|
-401 M | $ 106.6 | 1.65 % | $ 13.1 B | ||
|
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
589 M | - | -9.16 % | $ 8.49 B | ||
|
Lantheus Holdings
LNTH
|
522 M | $ 67.04 | - | $ 4.64 B | ||
|
Koninklijke Philips N.V.
PHG
|
553 M | $ 32.03 | -2.72 % | $ 20 B | ||
|
IDEXX Laboratories
IDXX
|
1.26 B | - | - | $ 53.5 B | ||
|
Illumina
ILMN
|
-479 M | $ 117.01 | -1.95 % | $ 18.6 B | ||
|
IQVIA Holdings
IQV
|
3.32 B | $ 176.27 | - | $ 32 B | ||
|
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
51.1 M | - | -0.62 % | $ 28.7 B | ||
|
Biodesix
BDSX
|
-28.7 M | - | - | $ 1.33 B | ||
|
NeoGenomics
NEO
|
-53 M | $ 11.47 | - | $ 1.45 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.73 B | $ 289.4 | 1.75 % | $ 24.3 B | ||
|
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.56 | -4.56 % | $ 1.91 M | ||
|
ICON Public Limited Company
ICLR
|
1.59 B | - | - | $ 11 B | ||
|
Natera
NTRA
|
-524 M | - | -0.5 % | $ 20.7 B | ||
|
Quidel Corporation
QDEL
|
1.11 B | - | -3.13 % | $ 1.19 B | ||
|
Biomerica
BMRA
|
-5.05 M | $ 2.23 | - | $ 5.12 M | ||
|
Bioventus
BVS
|
-24.4 M | $ 8.04 | - | $ 504 M |